FDA grants priority review to KTE X 19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. Kite/Gilead.
Related news and insights
Kite, a Gilead Company announced that the European Commission has granted conditional marketing authorization for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19).
Bristol Myers Squibb announced data from multiple studies evaluating lisocabtagene maraleucel (liso-cel), an investigational CD19-directed chimeric antigen receptor (CAR) T cell therapy, in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in relapsed or refractory mantle cell lymphoma (MCL) were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
Long-term follow-up results from the positive ACE-LY-004 Phase II trial showed patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression free for a median of 22 months , with median overall survival not yet reached at three years of follow-up.